Roc Rock Biotechnology Secures Ethical Approval for CAR-M Therapy in Ovarian Cancer
China-based Roc Rock Biotechnology Co., Ltd. has announced that it has received ethical approval from...
Landmark Biosecure Act Passes US House Committee with 40-1 Vote, Eyes 2024 Enactment
The US House Committee on Oversight and Accountability has completed the markup process for amendments...
Novo Holdings Gains Controlling Interest in Biopharma Equipment Supplier Single Use Support
Novo Nordisk’s (CPH: NOVO-B) controlling shareholder, Novo Holdings, has entered into an agreement to purchase...
AstraZeneca and BenevolentAI Reach Milestone in Heart Failure Target Validation
AstraZeneca (AZ; NASDAQ: AZN) has announced the successful experimental validation of a groundbreaking heart failure...
Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO
Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic...
Lifetech Scientific’s IBS Stent Demonstrates Non-Inferiority in Phase II Trial
Lifetech Scientific Corporation (HKG: 1302), a biopharmaceutical company based in China, has announced the completion...
Olymvax Biopharmaceuticals Gets Green Light for Tetravalent Influenza Vaccine Clinical Trial
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...
Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors
China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing...
GE HealthCare Partners with Shanghai Pudong for USD 52.5 Million Medical Tech Investment
GE HealthCare (NASDAQ: GEHC), a leading medical technology firm, has entered into a cooperation intent...
Vision Medicals Raises Hundreds of Millions in Series D+ Round to Advance Molecular Diagnostics
Guangdong-based Vision Medicals has reportedly secured hundreds of millions of renminbi in a Series D+...
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ:...
Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China
Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion...
Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch
Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...
Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round
China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in...
US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports
The US Office of the Trade Representative (USTR) has announced a series of stringent new...
Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation
Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about...
Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Zai Lab Advances Vygart Hytrulo for CIDP with sBLA Filing in China
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...
Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication
GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals...